🇺🇸 FDA
Patent

US 11372002

Assays for determining plasma kallikrein system biomarkers

granted A61KA61K2039/505A61P

Quick answer

US patent 11372002 (Assays for determining plasma kallikrein system biomarkers) held by Takeda Pharmaceutical Company Limited expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61P, A61P29/00, A61P43/00